A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

While GLP-1 medications like Ozempic and Wegovy ... remain manageable Insurance coverage continues expanding New formulations ...

In 2024, new medicines changed how we think about healthy weight loss—but psychological factors remain just as important as ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...